Andrew Gengos Buys 10,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Andrew Gengos bought 10,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were bought at an average price of $3.73 per share, with a total value of $37,300.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at $37,300. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Gengos also recently made the following trade(s):

• On Monday, June 16th, Andrew Gengos bought 5,000 shares of Terns Pharmaceuticals stock. The shares were purchased at an average price of $3.95 per share, for a total transaction of $19,750.00.

Terns Pharmaceuticals Price Performance

NASDAQ TERN traded up $0.10 during midday trading on Thursday, hitting $4.00. The company had a trading volume of 749,211 shares, compared to its average volume of 1,498,111. The firm has a 50-day moving average price of $3.12 and a 200-day moving average price of $3.99. Terns Pharmaceuticals, Inc. has a twelve month low of $1.87 and a twelve month high of $11.40.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03. As a group, equities analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several hedge funds have recently bought and sold shares of TERN. Thrive Wealth Management LLC bought a new stake in shares of Terns Pharmaceuticals during the 1st quarter worth approximately $29,000. Vontobel Holding Ltd. acquired a new position in Terns Pharmaceuticals during the first quarter valued at approximately $39,000. Dynamic Technology Lab Private Ltd bought a new stake in Terns Pharmaceuticals during the first quarter worth $51,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Terns Pharmaceuticals in the 4th quarter valued at $73,000. Finally, Townsquare Capital LLC acquired a new stake in shares of Terns Pharmaceuticals in the 4th quarter valued at $76,000. 98.26% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TERN. BMO Capital Markets dropped their price target on Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. JMP Securities reissued a "market outperform" rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a report on Monday, April 21st. Finally, William Blair reissued a "market perform" rating on shares of Terns Pharmaceuticals in a research report on Friday, March 21st. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.63.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.